Glenmark Pharmaceuticals Limited has informed the Exchange regarding a Press Release dated September 15, 2015 titled ”Glenmark’s Bi-Specific Antibody – GBR 1302 to enter Phase I trials”……
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
